Elicera Therapeutics got 2.5 MEUR grant to finance a clinical phase I/II-trial with CAR T-cell therapy

GAEU Consulting secures the prestigious EIC Accelerator funding for Elicera Therapeutics, a clinical stage cell and gene therapy company that develops next generation immuno-oncology treatments based on enhanced oncolytic viruses and CAR T-cells. The 2.5 MEUR grant will be used to finance a clinical phase I/II-trial with Elicera’s CAR T-cell therapy, ELC-301.

Tomasz Wąsik, MBA comments: “we are extremely happy to add Elicera Therapeutics to our portfolio of successful EIC Accelerator life science projects. The project has all it takes to get the funding – a breakthrough deep-tech innovation, a dedicated team and a clear project plan. It was a real pleasure guiding Elicera team all the way to this success.”

Jamal El-Mosleh, CEO, Elicera Therapeutics AB comments: “The support we have received from GAEU has been very professional and dedicated in addition to it being a great pleasure on a personal level as well to collaborate with the entire GAEU-team on securing this very important EIC-grant for Elicera.”